DF/HCC Clinical Research Community,

It is with sincere appreciation that we announce the retirement of Nareg Grigorian, the Director of the Office of Data Quality (ODQ) supporting clinical research across Dana-Farber/Harvard Cancer Center. Nareg’s many years of service, and his in-depth working knowledge within the Office of Data Quality and across the DF/HCC Consortium have advanced the department’s mission supporting study activation and data management.

Nareg Grigorian

Nareg steps down after fourteen years with DF/HCC, working collaboratively across all functions of clinical research administration. He joined the department in 2011 as the Manager of the Internal Auditing Program and for the last year served as the department’s Director overseeing clinical trials data safety, internal audit, investigator-initiated trial data management, policy and training, study activation, and co-chair of DF/HCC’s Clinical Operations Committee. In past roles, Nareg has mentored and developed staff within the ODQ Auditing Team while acting as a resource to the DF/HCC Research Community and Oversight Committees. Nareg has also served on two DFCI IRB panels throughout his tenure.

Please join us in congratulating Nareg on his September 30, 2025 retirement. We wish him well and have begun a national search for his successor.

Sincerely,

Rebecca Heist, MD
Professor of Medicine, Harvard Medical School
Medical Director, Clinical Trials Operations, DF/HCC
Lee Albright and Nile Albright MD Endowed Chair in Clinical Cancer Research, Massachusetts General Hospital

Jeffrey Meyerhardt, MD, MPH, FASCO
Professor of Medicine, Harvard Medical School
Associate Director, Clinical Trials, DF/HCC
Douglas Gray Woodruff Chair in Colorectal Cancer Research,
Chief Clinical Research Officer, Dana-Farber Cancer Institute

Kyle Bird, MHA
VP, Clinical Research Management, Dana-Farber Cancer Institute,
Dana-Farber/Harvard Cancer Center